Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Jnana Therapeutics is raising $59,999,998.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Joanne Kotz played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Jnana Therapeutics
Jnana Therapeutics is a biotechnology company utilizing a next generation chemoproteomic platform to address well-validated but hard-to-drug targets, including the solute carrier (SLC) family of metabolite transporters. Jnana is focused on developing best-in-class therapies to treat a wide range of diseases, including immune-mediated, neurological and metabolite-dependent diseases. Headquartered in Boston, Jnana is founded by world-renowned scientists and backed by leading life science investors. For more information, please visit www.jnanatx.com and follow us on Twitter and on LinkedIn.

To learn more about Jnana Therapeutics, visit http://www.jnanatx.com/

Contact:
Joanne Kotz, President and Chief Executive Officer
857-349-9200

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved